Vancouver General Hospital
http://www.vch.ca/Locations-Services/result?res_id=644
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Vancouver General Hospital
Tech Transfer Deals, January 2016
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Tech Transfer Deals column provides a monthly update on technology transfer deals, reporting licensing agreements between companies and universities or other research institutions within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced November through December 2015.
OncoGeneX Technologies Inc.
OncoGeneX Technologies was founded specifically to develop OGX-011, a compound that inhibits the production of clusterin, a cell survival protein found to be up-regulated in many cancers after exposure to standard cancer therapies including chemotherapy, radiation therapy, and hormone ablation.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice